Rankings
▼
Calendar
LGND FY 2025 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
LGND
Ligand Pharmaceuticals Incorporated
$4B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$268M
+60.4% YoY
Gross Profit
$261M
97.5% margin
Operating Income
$47M
17.6% margin
Net Income
$124M
46.4% margin
EPS (Diluted)
$6.13
Cash Flow
Operating Cash Flow
$49M
Free Cash Flow
$49M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$1.6B
Total Liabilities
$543M
Stockholders' Equity
$1.0B
Cash & Equivalents
$175M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$268M
$167M
+60.4%
Gross Profit
$261M
$156M
+67.6%
Operating Income
$47M
-$23M
+308.8%
Net Income
$124M
-$4M
+3186.6%
← Q4 2024
All Quarters
Q1 2025 →